Market News / Story
Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share
Seeking Alpha ·
Seeking Alpha reports: TRex Bio prices IPO at $14 per share, offering 8.33 million shares to the public, as the clinical-stage biotech company focuses on developing immunoregulatory medicines targeting tissue regulatory T-cell (Treg) biology. The biotech firm had offered shares for $14 to $16 each, an earlier filing showed. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $116.7…